Chemotherapy and Radiotherapy for Small-Cell Lung Cancer
Author Information
Author(s): N.M. Bleehen, D.J. Girling, A. Gregor, R.C.F. Leonard, D. Machin, C.G. McKenzie, D.A.L. Morgan, J.F. Smyth, M.F. Spittle, R.J. Stephens, H.M.A. Yosef
Primary Institution: MRC Clinical Oncology and Radiotherapeutics Unit, Addenbrooke's Hospital, Cambridge
Hypothesis
Can alternating chemotherapy and radiotherapy improve treatment outcomes for small-cell lung cancer?
Conclusion
The study found that while the alternating regimen was feasible for some patients, it resulted in significant toxicity and only moderate response rates.
Supporting Evidence
- 14 out of 22 patients with confirmed small-cell disease had a complete response.
- 77% total response rate was observed among the patients.
- Myelosuppression was the most common serious adverse effect, affecting 19 of the 24 patients.
- Treatment was considered a contributory cause of death in four patients.
- Only one patient treated with the higher cisplatin dose completed the treatment.
Takeaway
Doctors tried a new way to treat lung cancer by mixing chemotherapy and radiation, but many patients got really sick from the treatment.
Methodology
Patients received alternating chemotherapy and radiotherapy, with dosages adjusted due to toxicity.
Potential Biases
The study was non-randomized, which may introduce selection bias.
Limitations
The study was non-randomized and had a small sample size, limiting the generalizability of the results.
Participant Demographics
19 men and 5 women, aged 70 years or less, with previously untreated small-cell lung cancer.
Statistical Information
Confidence Interval
95% CI 60 to 95%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website